Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer

References

• Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, . NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Cancer Network 2010;8:162–200.
   PubMedGoogle Scholar
• Nichol AM, Warde P, Bristow RG. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: Clinical and translational issues. Cancer 2005;104:891–905.
   PubMedGoogle Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
   PubMed Web of Science ®Google Scholar
• Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009;27: 4321–6.
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH, Evans A, Lockwood G, Tkachuk D, Bostwick DG, Epstein JI, . Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol 2010;34:169–77.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Natl Clin Pract Oncol 2007;4:632–42.
   PubMedGoogle Scholar
• Roach M, 3rd, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009;115(13 Suppl):3112–20.
   PubMedGoogle Scholar
• Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524–31.
   PubMed Web of Science ®Google Scholar
• Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, . Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 2007;67: 8229–39.
   Google Scholar
• Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275(5308):1943–7.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644–8.
   PubMedGoogle Scholar
• Ishkanian AS, Malloff CA, Watson SK, DeLeeuw RJ, Chi B, Coe BP, . A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004;36: 299–303.
   PubMed Web of Science ®Google Scholar
• Ishkanian AS, Mallof CA, Ho J, Meng A, Albert M, Syed A, . High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091–100.
   PubMedGoogle Scholar
• Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, . Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504–10.
   PubMed Web of Science ®Google Scholar
• Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8: 180–92.
   PubMed Web of Science ®Google Scholar
• Bristow RG, Ozcelik H, Jalali F, Chan N, Vesprini D. Homologous recombination and prostate cancer: A model for novel DNA repair targets and therapies. Radiother Oncol 2007;83: 220–30.
   PubMed Web of Science ®Google Scholar
• Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, . Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1: 315–22.
   PubMed Web of Science ®Google Scholar
• Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008;7:993–9.
   PubMed Web of Science ®Google Scholar
• Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol 2008;86:407–11.
   PubMed Web of Science ®Google Scholar
• Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, . Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010;102:570–6.
   PubMedGoogle Scholar
• Prensner JR, Chinnaiyan AM. Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev 2009;19: 82–91.
   PubMedGoogle Scholar
• Burri J, Haldimann M, Dudler V. Selenium status of the Swiss population: Assessment and change over a decade. J Trace Elem Med Biol 2008;22:112–9.
   PubMed Web of Science ®Google Scholar
• Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, . Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006;12:2545–54.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Keyes M, Barclay L, Delaney A, Krzywinski M, Thomas D, . Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res 2009;15:5008–16.
   PubMedGoogle Scholar